Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
AASLD: Successful HCV Tx cuts deaths post-transplant

After a liver transplant, successful treatment for hepatitis C significantly reduces the risk of death, researchers reported here.

Published
01 November 2010
From
MedPage Today
Gilead presents phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

Published
01 November 2010
From
The Medical News
Longer Hep C Treatment Improves Response in People Coinfected With HIV

People coinfected with both HIV and hepatitis C virus (HCV) who fail to respond rapidly to HCV treatment are more likely to achieve a cure for their HCV if they extend their treatment by at least six months. These data were presented at the American Association for the Study of Liver Diseases being held October 29 to November 2 in Boston.

Published
01 November 2010
From
AIDSMeds
Black patients fare well on Vertex hepatitis C drug

A closer look at data from a late stage trial of Vertex Pharmaceuticals Inc's eagerly anticipated hepatitis C drug telaprevir showed impressive cure rates for black patients and for patients with advanced liver disease.

Published
31 October 2010
From
Reuters
Investigational drug for hepatitis C boceprevir achieved significantly higher sustained virologic response rates compared to control

Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor.

Published
31 October 2010
From
Digital Journal
Bristol-Myers, Gilead seek AIDS cocktail success in hepatitis C

Bristol-Myers Squibb Co. and Gilead Sciences Inc., makers of the top-selling combination pills for AIDS, are trying to duplicate their success to combat another evasive virus, hepatitis C. The companies are among about a dozen that are developing drug cocktails more effective, less toxic and easier to take than current therapy.

Published
30 October 2010
From
Bloomberg
Hepatitis C drug pipeline analysis and market forecasts to 2016

GlobalData has released a pharmaceutical and healthcare report, "Hepatitis C-Drug Pipeline Analysis and Market Forecasts to 2016".

Published
27 October 2010
From
Press release
Vertex Pharmaceuticals highlights progress in hepatitis C drug development

Vertex Pharmaceuticals issues a status report on plans for licensing of its HCV protease inhibitor telaprevir, and announces details of further studies.

Published
27 October 2010
From
Vertex
Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

Published
10 October 2010
From
Eurekalert Medicine & Health
NICE’s publishes 200th guidance to better tackle Hepatitis C

The new guidance updates existing recommendations on the use of peginterferon alfa and ribavirin, allowing for wider use and, if appropriate, shorter treatment regimens for patients with the disease.

Published
27 September 2010
From
Pharma Times

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.